Tags

Type your tag names separated by a space and hit enter

Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
J Cardiovasc Pharmacol. 2008 Jan; 51(1):18-23.JC

Abstract

It is suggested that angiotensin II is involved in the pathogenesis of pulmonary hypertension and subsequent right ventricular hypertrophy; therefore, an angiotensin AT1 receptor antagonist could be beneficial for the treatment of this disease. We tested the effect of the new AT1 receptor antagonist olmesartan medoxomil on monocrotaline-induced pulmonary hypertension in rats. At 3 weeks after a single subcutaneous injection of monocrotaline (50 mg/kg), the lung/body weight ratio, the right ventricle/(left ventricle plus septum) weight ratio [RV/(LV+S)], and right ventricular systolic pressure were increased, indicating establishment of pulmonary hypertension and right ventricular hypertrophy. Oral administration of olmesartan medoxomil (2 or 5 mg/kg/day for 3 weeks) restored RV/(LV+S) and right ventricular systolic pressure, and a higher dose (5 mg/kg/day) improved the lung/body weight ratio. Pulmonary arteries isolated from monocrotaline-treated rats exhibited an increase in basal tone in the resting state, indicating that they had intrinsic tone. Three weeks of treatment with olmesartan decreased this intrinsic tone. These data suggest that long-term treatment with olmesartan has beneficial effects on monocrotaline-induced pulmonary hypertension and subsequent right ventricular hypertrophy.

Authors+Show Affiliations

Department of Veterinary Pharmacology and Anatomy, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18209564

Citation

Kato, Tomohiro, et al. "Evaluation of Olmesartan Medoxomil in the Rat Monocrotaline Model of Pulmonary Hypertension." Journal of Cardiovascular Pharmacology, vol. 51, no. 1, 2008, pp. 18-23.
Kato T, Nasu T, Sonoda H, et al. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension. J Cardiovasc Pharmacol. 2008;51(1):18-23.
Kato, T., Nasu, T., Sonoda, H., Ito, K. M., Ikeda, M., & Ito, K. (2008). Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension. Journal of Cardiovascular Pharmacology, 51(1), 18-23. https://doi.org/10.1097/FJC.0b013e318159b01c
Kato T, et al. Evaluation of Olmesartan Medoxomil in the Rat Monocrotaline Model of Pulmonary Hypertension. J Cardiovasc Pharmacol. 2008;51(1):18-23. PubMed PMID: 18209564.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension. AU - Kato,Tomohiro, AU - Nasu,Tetsuo, AU - Sonoda,Hiroko, AU - Ito,Kaoru M, AU - Ikeda,Masahiro, AU - Ito,Katsuaki, PY - 2008/1/23/pubmed PY - 2008/4/4/medline PY - 2008/1/23/entrez SP - 18 EP - 23 JF - Journal of cardiovascular pharmacology JO - J Cardiovasc Pharmacol VL - 51 IS - 1 N2 - It is suggested that angiotensin II is involved in the pathogenesis of pulmonary hypertension and subsequent right ventricular hypertrophy; therefore, an angiotensin AT1 receptor antagonist could be beneficial for the treatment of this disease. We tested the effect of the new AT1 receptor antagonist olmesartan medoxomil on monocrotaline-induced pulmonary hypertension in rats. At 3 weeks after a single subcutaneous injection of monocrotaline (50 mg/kg), the lung/body weight ratio, the right ventricle/(left ventricle plus septum) weight ratio [RV/(LV+S)], and right ventricular systolic pressure were increased, indicating establishment of pulmonary hypertension and right ventricular hypertrophy. Oral administration of olmesartan medoxomil (2 or 5 mg/kg/day for 3 weeks) restored RV/(LV+S) and right ventricular systolic pressure, and a higher dose (5 mg/kg/day) improved the lung/body weight ratio. Pulmonary arteries isolated from monocrotaline-treated rats exhibited an increase in basal tone in the resting state, indicating that they had intrinsic tone. Three weeks of treatment with olmesartan decreased this intrinsic tone. These data suggest that long-term treatment with olmesartan has beneficial effects on monocrotaline-induced pulmonary hypertension and subsequent right ventricular hypertrophy. SN - 0160-2446 UR - https://www.unboundmedicine.com/medline/citation/18209564/Evaluation_of_olmesartan_medoxomil_in_the_rat_monocrotaline_model_of_pulmonary_hypertension_ L2 - https://doi.org/10.1097/FJC.0b013e318159b01c DB - PRIME DP - Unbound Medicine ER -